Product Center
The launch ceremony of the four valent influenza virus subunit vaccine Huierkangxin was successfully held!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26
- Views:
(Summary description)On September 25th, the inaugural ceremony of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
The launch ceremony of the four valent influenza virus subunit vaccine Huierkangxin was successfully held!
(Summary description)On September 25th, the inaugural ceremony of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26 10:00
- Views:
On September 25th, the inaugural ceremony of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
At the inaugural ceremony, Mr. An Youcai, Chairman and General Manager, reviewed the eight years of hard work, affirmed his achievements, and looked forward to the future. He proposed that only through innovation can we go far, and we must firmly adhere to the five-year strategic goals, forge ahead, and jointly build a defense line for human health!
The official launch of Huier Kangxin will bring society more advanced, safer, and effective choices for influenza vaccination, reduce hesitation in vaccination, further improve the influenza vaccination rate, and assist in China's influenza prevention and control!
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
